Estriol acts as a GPR30 antagonist in estrogen receptor-negative breast cancer cells.
about
GPER Function in Breast Cancer: An OverviewThe G-protein-coupled estrogen receptor GPER in health and diseaseGPER is involved in the stimulatory effects of aldosterone in breast cancer cells and breast tumor-derived endothelial cellsEstrogen biology: new insights into GPER function and clinical opportunitiesEffects of atrazine on estrogen receptor α- and G protein-coupled receptor 30-mediated signaling and proliferation in cancer cells and cancer-associated fibroblastsExogenous hormonal regulation in breast cancer cells by phytoestrogens and endocrine disruptorsCopper activates HIF-1α/GPER/VEGF signalling in cancer cellsG protein-coupled estrogen receptor in energy homeostasis and obesity pathogenesis.Nuclear-encoded mitochondrial MTO1 and MRPL41 are regulated in an opposite epigenetic mode based on estrogen receptor status in breast cancer.GPCRs and cancerAlternate estrogen receptors promote invasion of inflammatory breast cancer cells via non-genomic signalingMIBE acts as antagonist ligand of both estrogen receptor α and GPER in breast cancer cells.Combinations of physiologic estrogens with xenoestrogens alter calcium and kinase responses, prolactin release, and membrane estrogen receptor trafficking in rat pituitary cells.Minireview: G protein-coupled estrogen receptor-1, GPER-1: its mechanism of action and role in female reproductive cancer, renal and vascular physiologyGPER mediates cardiotropic effects in spontaneously hypertensive rat hearts.Novel Aspects Concerning the Functional Cross-Talk between the Insulin/IGF-I System and Estrogen Signaling in Cancer Cells.Inhibition of GPR30 by estriol prevents growth stimulation of triple-negative breast cancer cells by 17β-estradiol.G-protein Coupled Estrogen Receptor 1 Expression in Primary Breast Cancers and Its Correlation with Clinicopathological Variables.International Union of Basic and Clinical Pharmacology. XCVII. G Protein-Coupled Estrogen Receptor and Its Pharmacologic ModulatorsPregnancy Augments G Protein Estrogen Receptor (GPER) Induced Vasodilation in Rat Uterine Arteries via the Nitric Oxide - cGMP Signaling PathwayThe effects of (-)-epicatechin on endothelial cells involve the G protein-coupled estrogen receptor (GPER).Inactivation of GPR30 reduces growth of triple-negative breast cancer cells: possible application in targeted therapy.Effect of tumour necrosis factor-alpha on estrogen metabolic pathways in breast cancer cells.A calixpyrrole derivative acts as an antagonist to GPER, a G-protein coupled receptor: mechanisms and models.SIRT1 is involved in oncogenic signaling mediated by GPER in breast cancer.Macromolecular Modelling and Docking Simulations for the Discovery of Selective GPER Ligands.G protein-coupled estrogen receptor mediates the up-regulation of fatty acid synthase induced by 17β-estradiol in cancer cells and cancer-associated fibroblasts.Recent Advances on the Role of G Protein-Coupled Receptors in Hypoxia-Mediated Signaling.Alike but not the same: anatomic heterogeneity of estrogen receptor-mediated vasodilation.HIF-1α/GPER signaling mediates the expression of VEGF induced by hypoxia in breast cancer associated fibroblasts (CAFs)Potential of olive oil phenols as chemopreventive and therapeutic agents against cancer: a review of in vitro studies.Combating malaria with plant molecules: a brief update.Management of menopause in women with breast cancer.Genetic, Epigenetic, and Environmental Factors Influencing Neurovisceral Integration of Cardiovascular Modulation: Focus on Multiple Sclerosis.Identification of the estrogen receptor GPER in neoplastic and non-neoplastic human testes.GPER Mediates Non-Genomic Effects of Estrogen.GPER modulators: Opportunity Nox on the heels of a class Akt.G Protein-Coupled Estrogen Receptor (GPER) Agonist Dual Binding Mode Analyses toward Understanding of its Activation Mechanism: A Comparative Homology Modeling ApproachGPER-1/GPR30 a novel estrogen receptor sited in the cell membrane: therapeutic coupling to breast cancer.Diverse Synaptic Distributions of G Protein-coupled Estrogen Receptor 1 in Monkey Prefrontal Cortex with Aging and Menopause.
P2860
Q21131274-6AFB3CB6-7C48-4E03-AF58-A28D6351C77BQ27013052-0048A9D2-3D3F-4865-ADC0-D1A95E3F8360Q27340035-A7285048-A1CD-4853-98C6-9E4763D8F301Q28307726-BC8B2912-5F7B-4157-99AB-F1A37FF8AE14Q28393409-1848EAD6-5802-47EC-8C5C-7EC92DE13783Q28393495-C006D8A5-061F-4584-92DC-834FC5A5571FQ28601324-9211C7E0-7DAA-4A02-9749-39B78C0460CCQ30425896-6BFDCD30-0732-4B29-A8F7-586BC7D128B0Q33588369-27961351-B43E-443E-AE1E-DD83F70572F7Q33828719-AC279D6E-5A31-4B08-836E-15EDAFDFAA43Q34147662-5AECD5B9-6263-4748-837C-848EAE17979CQ34247686-2B0024B4-A4F2-4188-A114-B629D89DD010Q34258178-2860BC07-B431-4B3D-8B3B-1C8CCAB38B9AQ34267558-83494689-1423-41E5-B1FC-A65A1CE602E8Q34946257-570C1B35-A114-4156-BA15-A3C1E8D536FAQ35153546-40320703-A17F-428D-9344-0B2FF5AD29AFQ35191464-F30ED5AB-36B2-47E2-BF60-615DE8A77DA3Q35435464-A396FB89-ACE3-4B39-9F6C-2B02EBAB4E25Q35795751-D9FB14D2-DC61-4D74-9D67-169E32339107Q35832036-616D53A9-9E34-454A-BA7B-111668FEB5BBQ36014772-AE46AEBD-7451-4F54-9F60-D290D10027E0Q36095938-892F6E83-6A3A-4E53-A0A4-72E3355585BDQ36128919-D028B2DD-984A-4D48-BAC3-9B7091EF2E9CQ36175376-41CCC7D0-6739-42D7-A534-8A15F5326813Q36293908-85627975-E11F-4235-A17A-B462973E92A9Q36445127-E5B90A33-0F48-4816-B658-62D918F545F7Q36481702-43439DCA-9938-4993-A1D7-BA4145EFD8EDQ36653897-FD45D529-56BC-4237-B047-D64F687CE41DQ37030029-38298A2E-4C01-406A-9B1A-EF26FD6D3CBBQ37690722-60ACE7BD-7322-4163-B7CB-5AD4340AED1CQ38063484-EE4C01F5-2519-4C54-82AA-3E43569BA87FQ38155893-E080AAE1-F100-4467-8CFF-B49401CD052AQ38298951-0A3818D7-59FC-4D0B-81CF-661AF8882B5BQ38616570-705662D4-2794-4087-B19F-27E4B98EC3C1Q38806304-B1A7429F-CDA4-46B4-93F0-5863732C2CB0Q38818348-244870E9-E377-4450-86ED-B6401E377A22Q39174507-246D90E7-CBD9-47E1-9F49-E31FA6FE2052Q39395077-2A3BC542-9CB5-44DD-916D-A92E86C8B095Q39410745-AE727D72-A6B8-4B95-9717-5C8D568FCC3DQ39949038-760D54E9-EA15-4A7D-9B18-4CA0456D1B2A
P2860
Estriol acts as a GPR30 antagonist in estrogen receptor-negative breast cancer cells.
description
2010 nî lūn-bûn
@nan
2010 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Estriol acts as a GPR30 antagonist in estrogen receptor-negative breast cancer cells.
@ast
Estriol acts as a GPR30 antagonist in estrogen receptor-negative breast cancer cells.
@en
Estriol acts as a GPR30 antagonist in estrogen receptor-negative breast cancer cells.
@nl
type
label
Estriol acts as a GPR30 antagonist in estrogen receptor-negative breast cancer cells.
@ast
Estriol acts as a GPR30 antagonist in estrogen receptor-negative breast cancer cells.
@en
Estriol acts as a GPR30 antagonist in estrogen receptor-negative breast cancer cells.
@nl
prefLabel
Estriol acts as a GPR30 antagonist in estrogen receptor-negative breast cancer cells.
@ast
Estriol acts as a GPR30 antagonist in estrogen receptor-negative breast cancer cells.
@en
Estriol acts as a GPR30 antagonist in estrogen receptor-negative breast cancer cells.
@nl
P2093
P50
P1476
Estriol acts as a GPR30 antagonist in estrogen receptor-negative breast cancer cells
@en
P2093
Ernestina Marianna De Francesco
Paola De Marco
Rosamaria Lappano
P304
P356
10.1016/J.MCE.2010.02.006
P577
2010-02-06T00:00:00Z